Table 19 Characteristics of included studies- lymphoma
From: Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Baecklund E [245], 2006, Swedish | M/F | 196–1995 | From the Swedish Inpatient Register | 269 | 225 | Lymphoma | Hospital records | Use aspirin for 4 consecutive weeks | 15,16 | 5 |
Zhang YQ [246], 2006, US | M/F | 197–2002 | Subjects were recruited from patients admitted to hospitals in New York, Philadelphia, Boston and Baltimore | 412 | 1524 | Non-Hodgkin lymphoma | Nurse-interviewers administered standard questionnaires | Use at least four times per week for at least three or more continuous months(regular) | 1,2,7,8 | 7 |
Flick ED [247], 2006, US+ | M/F | 200–2004 | Population from the California counties of San Francisco, Alameda, Marin, Contra Costa, San Mateo, and Santa Clara | 604 | 638 | Non-Hodgkin lymphoma | Interview | Use at least 2 days per week for 3 months or longer during the past 20 years | 1,2,17 | 7 |
Baker JA [248], 2005, US | M/F | 198–1998 | RPCI | 628 | 2512 | Non-Hodgkin lymphoma | Questionnaire | Use at least once per week for 6 months | 1 | 5 |
Chang ET [249], 2004, US | M/F | 1997–2000 | population from the greater Boston, Massachusetts, metropolitan area and in the state of Connecticut | 565 | 679 | Hodgkin’s lymphoma | Telephone interview | Use two or more tablets per Week(regular) | 1,2,3,9,17 | 6 |
Zhang YW [250], 2004, US | M/F | 1996–2000 | Patients in Yale Cancer Center’s Rapid Case Ascertainment Shared Resource(RCA) | 601 | 717 | Non-Hodgkin lymphoma | Iinterview | Use at least once a day for a period of 6 months or longer previous to 1 year ago | 1,4,10,18 | 7 |
Cohort studies | ||||||||||
Hollestein LM [91], 2014, Netherlands a | M/F | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 256 | 109,276 | Lymphoma | Prescription database | Low dose aspirin (≤100 mg daily)- not further defined | 1,2,11,12 | 8 |
Birmann BM [251], 2014, US | F | 1976–2008 | NHS | 196 | 85,942 | Multiple myeloma | Questionnaire | 81-mg “baby” and 325-mg “adult” strength | 1,10 | 8 |
M | 1986–2008 | HPFS | 132 | 47,029 | Multiple myeloma | Questionnaire | 81-mg “baby” and 325-mg “adult” strength | 1,10 | 8 | |
Teras LR [252], 2013, US | M/F | 1992–2007 | The CPS-II Nutrition Cohort Cancer Prevention Study-II (CPS-II) Nutrition Cohort | 1709 | 149,570 | Lymphoma | Questionnaire | Use aspirin ≥30 aspirin pills/Month(regular) | 1,3,4,5,6,10,19,20, 21,22,23,24,25 | 7 |
Chang ET [253], 2011, Denmarka | M/F | 1995–2008 | Population from Denmark | 1659 | 8089 | Hodgkin lymphoma | Prescription database | Use aspirin ≥ 2 times per week | 1,2,13,14 | 8 |
Walter RB [254], 2011, US | M/F | 2000–2002 | VITAL Study | 224 | 64,839 | Lymphoma | Questionnaire | Had ever taken low dose aspirin(81 mg) | 4,21,23,26,27,28,29,33 | 6 |
Erber E [255], 2009, US | M/F | 199–1996 | MEC Study | 896 | 193,050 | Non-Hodgkin Lymphoma | Self-completed questionnaire | Use at least two times per week for 1 month or longer | 5,6,10 | 8 |
Cerhan JR [256], 2003, US | M/F | 199–1999 | IWHS | 130 | 27,290 | Non-Hodgkin Lymphoma | Self-completed questionnaire | Had ever taken aspirin- not further defined | 1,3,6,17,21,25, 29,30,31,32 | 7 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 57 | 29,470 | Non-Hodgkin’s lymphoma | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 48 | 12,668 | Lymphoma | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |